Trial Profile
A single dose, parallel group study to evaluate pharmacokinetics of isavuconazole administered as prodrug isavuconazonium sulfate in healthy volunteers with mild and moderate hepatic impairment due to hepatitis B or C
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Oct 2017
Price :
$35
*
At a glance
- Drugs Isavuconazonium (Primary) ; Isavuconazonium (Primary)
- Indications Aspergillosis; Candidiasis; Zygomycosis
- Focus Pharmacokinetics
- 31 Oct 2017 New trial record
- 01 May 2016 Results (n=96) of development and validation of population pharmacokinetic model published in the Antimicrobial Agents and Chemotherapy